In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation (scientific article published in September 2002)

The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin

Q41814617

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

Q43856527

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

Q43856529

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

Q44017888

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

Q44017891

ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary

Q58975787

Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin

Q67552412

Heparin

Q70147507

Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris

Q73291983

Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular weight heparin in hemodialysis

Q73386865

The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies

Q78981048

P433

issue

P921

main subject

heparin

Q190016

P304

page(s)

241-244

P577

publication date

2002-09-01

P1433

published in

Thrombosis Research

Q15758741

P1476

title

In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation

P478

volume

107

Reverse relations

cites work (P2860)

Q43241176	Administration of dalteparin based on the activated clotting time for prophylaxis of hepatic vessel thrombosis in living donor liver transplantation
Q28088534	Anticoagulation and antiplatelets as prophylaxis for hepatic artery thrombosis after liver transplantation
Q36844544	Antiphospholipid syndrome: laboratory testing and diagnostic strategies
Q38186094	Contemporary anticoagulation therapy in patients undergoing percutaneous intervention
Q51541734	Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.
Q90251579	Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis
Q34336597	Functional characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from Pichia pastoris
Q51232224	Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.
Q37834646	Laboratory assessment of new anticoagulants
Q37963792	Laboratory diagnosis of the lupus anticoagulant
Q45865979	Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology
Q35549780	Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays
Q24681351	New anticoagulants for the prevention and treatment of venous thromboembolism
Q90429121	Perioperative thromboprophylaxis in liver transplant patients
Q34052232	Role of factor xa inhibitors in cancer-associated thrombosis: any new data?
Q36326716	Spontaneous complete recovery of paraplegia caused by epidural hematoma complicating epidural anesthesia: a case report and review of literature

P356	DOI	10.1016/S0049-3848(02)00340-7
P8608	Fatcat ID	release_m5pf2oe3l5h5vd47rba7wxmz6e
P698	PubMed publication ID	12479885